v3.26.1
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2026
Fair Value Measurements  
Schedule of Assets/Liabilities Measured at Fair Value on Recurring Basis

Fair Value Measurement at June 30, 2026 and December 31, 2025

Quoted Price in Active

Market for Identical

Significant Other

Significant

Instruments

Observable Inputs

Unobservable Inputs

Level 1

Level 2

Level 3

Total

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Assets

  ​

  ​

  ​

  ​

  ​

  ​

  ​

  ​

Cash and cash equivalents

$

2,544

(1)  

$

3,072

(1)  

$

38,705

$

33,716

$

$

$

41,249

$

36,788

Processa common shares

$

2

(2)  

$

2

(2)  

$

$

$

$

$

2

$

2

(1)

The Company held approximately $2,544 in cash accounts as of June 30, 2026, of which approximately $404 was held in foreign currencies (translated into U.S. dollars). As of December 31, 2025, the Company held approximately $3,072 in cash of which approximately $481 was in foreign currencies (translated into U.S. dollars).

(2)

The Company holds 51 unrestricted common shares of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA).